An FDA for Financial Innovation: Applying the Insurable Interest Doctrine to 21st Century Financial Markets
Eric A. Posner
University of Chicago - Law School
E. Glen Weyl
University of Chicago; University of Toulouse 1 - Toulouse School of Economics
June 4, 2012
Northwestern University Law Review, Vol. 107, Forthcoming
University of Chicago Institute for Law & Economics Olin Research Paper No. 589
U of Chicago, Public Law Working Paper No. 382
The financial crisis of 2008 was caused in part by speculative investment in complex derivatives. In enacting the Dodd-Frank Act, Congress sought to address the problem of speculative investment, but merely transferred that authority to various agencies, which have not yet found a solution. We propose that when firms invent new financial products, they be forbidden to sell them until they receive approval from a government agency designed along the lines of the FDA, which screens pharmaceutical innovations. The agency would approve financial products if they satisfy a test for social utility that focuses on whether the product will likely be used more often for insurance than for gambling. Other factors may be addressed if the answer is ambiguous. This approach would revive and make quantitatively precise the common-law insurable interest doctrine, which helped control financial gambling before deregulation in the 1990s.
Number of Pages in PDF File: 56
Keywords: gambling, insurance, pre-approval regulation, financial regulation
JEL Classification: D63, G28, K22Accepted Paper Series
Date posted: February 25, 2012 ; Last revised: July 30, 2013
© 2014 Social Science Electronic Publishing, Inc. All Rights Reserved.
This page was processed by apollo3 in 0.610 seconds